Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 53.8 EUR 0.19% Market Closed
Market Cap: 516.9m EUR
Have any thoughts about
Pharmanutra SpA?
Write Note

Intrinsic Value

The intrinsic value of one PHN stock under the Base Case scenario is 43.41 EUR. Compared to the current market price of 53.8 EUR, Pharmanutra SpA is Overvalued by 19%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHN Intrinsic Value
43.41 EUR
Overvaluation 19%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Pharmanutra SpA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PHN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PHN?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Pharmanutra SpA

Provide an overview of the primary business activities
of Pharmanutra SpA.

What unique competitive advantages
does Pharmanutra SpA hold over its rivals?

What risks and challenges
does Pharmanutra SpA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pharmanutra SpA.

Provide P/S
for Pharmanutra SpA.

Provide P/E
for Pharmanutra SpA.

Provide P/OCF
for Pharmanutra SpA.

Provide P/FCFE
for Pharmanutra SpA.

Provide P/B
for Pharmanutra SpA.

Provide EV/S
for Pharmanutra SpA.

Provide EV/GP
for Pharmanutra SpA.

Provide EV/EBITDA
for Pharmanutra SpA.

Provide EV/EBIT
for Pharmanutra SpA.

Provide EV/OCF
for Pharmanutra SpA.

Provide EV/FCFF
for Pharmanutra SpA.

Provide EV/IC
for Pharmanutra SpA.

Show me price targets
for Pharmanutra SpA made by professional analysts.

What are the Revenue projections
for Pharmanutra SpA?

How accurate were the past Revenue estimates
for Pharmanutra SpA?

What are the Net Income projections
for Pharmanutra SpA?

How accurate were the past Net Income estimates
for Pharmanutra SpA?

What are the EPS projections
for Pharmanutra SpA?

How accurate were the past EPS estimates
for Pharmanutra SpA?

What are the EBIT projections
for Pharmanutra SpA?

How accurate were the past EBIT estimates
for Pharmanutra SpA?

Compare the revenue forecasts
for Pharmanutra SpA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharmanutra SpA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharmanutra SpA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharmanutra SpA compared to its peers.

Compare the P/E ratios
of Pharmanutra SpA against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharmanutra SpA with its peers.

Analyze the financial leverage
of Pharmanutra SpA compared to its main competitors.

Show all profitability ratios
for Pharmanutra SpA.

Provide ROE
for Pharmanutra SpA.

Provide ROA
for Pharmanutra SpA.

Provide ROIC
for Pharmanutra SpA.

Provide ROCE
for Pharmanutra SpA.

Provide Gross Margin
for Pharmanutra SpA.

Provide Operating Margin
for Pharmanutra SpA.

Provide Net Margin
for Pharmanutra SpA.

Provide FCF Margin
for Pharmanutra SpA.

Show all solvency ratios
for Pharmanutra SpA.

Provide D/E Ratio
for Pharmanutra SpA.

Provide D/A Ratio
for Pharmanutra SpA.

Provide Interest Coverage Ratio
for Pharmanutra SpA.

Provide Altman Z-Score Ratio
for Pharmanutra SpA.

Provide Quick Ratio
for Pharmanutra SpA.

Provide Current Ratio
for Pharmanutra SpA.

Provide Cash Ratio
for Pharmanutra SpA.

What is the historical Revenue growth
over the last 5 years for Pharmanutra SpA?

What is the historical Net Income growth
over the last 5 years for Pharmanutra SpA?

What is the current Free Cash Flow
of Pharmanutra SpA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharmanutra SpA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharmanutra SpA

Current Assets 59.6m
Cash & Short-Term Investments 21.8m
Receivables 26.2m
Other Current Assets 11.7m
Non-Current Assets 52.2m
Long-Term Investments 438k
PP&E 25.4m
Intangibles 23.2m
Other Non-Current Assets 3.1m
Current Liabilities 28.3m
Accounts Payable 11.7m
Accrued Liabilities 3.4m
Short-Term Debt 1.7m
Other Current Liabilities 11.6m
Non-Current Liabilities 28.7m
Long-Term Debt 21.2m
Other Non-Current Liabilities 7.5m
Efficiency

Earnings Waterfall
Pharmanutra SpA

Revenue
152.2m EUR
Cost of Revenue
-6.2m EUR
Gross Profit
145.9m EUR
Operating Expenses
-112.6m EUR
Operating Income
33.3m EUR
Other Expenses
-13.7m EUR
Net Income
19.6m EUR

Free Cash Flow Analysis
Pharmanutra SpA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PHN Profitability Score
Profitability Due Diligence

Pharmanutra SpA's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional 3-Years Revenue Growth
72/100
Profitability
Score

Pharmanutra SpA's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

PHN Solvency Score
Solvency Due Diligence

Pharmanutra SpA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Short-Term Solvency
Long-Term Solvency
69/100
Solvency
Score

Pharmanutra SpA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHN Price Targets Summary
Pharmanutra SpA

Wall Street analysts forecast PHN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHN is 86.02 EUR with a low forecast of 78.78 EUR and a high forecast of 92.4 EUR.

Lowest
Price Target
78.78 EUR
46% Upside
Average
Price Target
86.02 EUR
60% Upside
Highest
Price Target
92.4 EUR
72% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PHN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PHN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Pharmanutra SpA Logo
Pharmanutra SpA

Country

Italy

Industry

Consumer products

Market Cap

516.9m EUR

Dividend Yield

1.58%

Description

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Contact

PISA
Pisa
Via delle Lenze n. 216/B
+390507846500
www.pharmanutra.it

IPO

2017-07-18

Employees

65

Officers

Chairman & President
Mr. Andrea Lacorte
Vice Chairman, MD & VP
Mr. Roberto Lacorte
Delegate Advisor, COO & Executive Director
Mr. Carlo Volpi
Scientific Director & Executive Director
Mr. Germano Tarantino

See Also

Discover More
What is the Intrinsic Value of one PHN stock?

The intrinsic value of one PHN stock under the Base Case scenario is 43.41 EUR.

Is PHN stock undervalued or overvalued?

Compared to the current market price of 53.8 EUR, Pharmanutra SpA is Overvalued by 19%.

Back to Top